Your session is about to expire
← Back to Search
Onalespib + Radiation Therapy + Cisplatin for Head and Neck Cancer
Study Summary
This trial is testing onalespib + IMRT + cisplatin to see if it's more effective than just IMRT + cisplatin at treating squamous cell carcinoma of the head and neck.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have or am at risk for serious eye problems like retinal detachment or macular degeneration.I have moderate to severe heart failure.I have hepatitis B or C, or HIV with a CD4 count of 500 or more and am not on antiviral agents.I am mostly active and can care for myself.I am using or will use birth control during and for 3 months after the study.I've been cancer-free for over 3 years or had non-melanoma skin cancer fully removed.I have had a heart attack, unstable angina, or a procedure to open my heart's arteries within the last 6 months.I am not HIV-positive or not on antiretroviral therapy.I have a confirmed, untreated squamous cell carcinoma in my mouth or throat.My condition is potentially treatable with radiation and cisplatin chemotherapy.My kidney function is normal or near normal.I have had radiation therapy for head or neck cancer.My cancer originates from the nasopharynx, paranasal sinus, skin, or is of unknown origin.My heart rhythm is stable, except for controlled atrial fibrillation.I am not currently using any herbal supplements.I have hearing loss that could get worse with certain cancer treatments.I have a history of heart problems.I do not have severe numbness, pain, or weakness in my hands or feet.My tumor is in stages T1-4, N2b-3, M0 and may be HPV+ with high risk features or HPV-.My cancer has spread to distant parts of my body.I do not have any serious illnesses or social situations that would stop me from following the study's requirements.My high blood pressure is not controlled by medication.
- Group 1: Treatment (onalespib, cisplatin, IMRT)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Has the Onalespib drug been officially sanctioned by the Food and Drug Administration?
"Taking into account its phase 1 status, which implies limited evidence of safety and efficacy, our team at Power gave onalespib a score of 1."
Are there any criteria that would exclude me from participating in this clinical experiment?
"Those wishing to qualify for this clinical trial must have laryngeal squamous cell carcinoma and be between 18-70 years old. Currently, the medical study is looking for 2 participants in total."
Are participants aged 35 and over eligible for this medical research?
"As detailed in the selection requirements, individuals who wish to take part must be aged 18 or above and not older than 70."
Are there any reports of prior experiments with Onalespib?
"Since 1997, when the first clinical trial of Onalespib was conducted at City of Hope Comprehensive Cancer Center, 1559 trials have come to completion. Currently there are 750 trials actively running; many taking place in New Haven, Connecticut."
Are there any vacancies within this research protocol for more participants?
"Regrettably, this trial is closed and no longer seeking participants. It was first published on September 21st 2015 with the latest update being November 16th 2022. However, there are currently 2676 active trials for laryngeal squamous cell carcinoma patients and 750 studies actively recruiting those taking Onalespib."
What is the enrollment quota for this research program?
"At present, this trial has ceased recruitment. It was initially posted on September 21st 2015 and the last update occured November 16th 2022. However, there are currently 2676 studies actively recruiting participants with laryngeal squamous cell carcinoma and 750 trials for Onalespib that are still enrolling patients."
What diseases does Onalespib generally target?
"Onalespib is a common treatment for advanced ovarian cancer and can be beneficial to those with conditions that are unresponsive to conventional therapies, metastatic neoplasms, or advance directives."
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger